Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZM001
- Development stage
- Phase 1
- Lead developer
- Immunochina Pharmaceuticals
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Injection
01
Overview
ZM001 is a CAR-T cell therapy developed by Beijing Immunochina Medical Science & Technology Co., Ltd. for the treatment of refractory systemic lupus erythematosus (SLE). It functions as a CD19 inhibitor, targeting B-lymphocyte antigen CD19.
- Other names
- ZM001 InjectionZM-001 InjectionZM 001 Injection
02
Targets
Beyond the preview
Go deeper on ZM001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZM001.